Similar articles for PMID: 24906866

Year	Number of Results
1977	1
1981	2
1982	1
1990	1
1991	1
1992	1
1997	2
1998	1
2000	2
2002	1
2003	1
2004	3
2005	2
2006	3
2007	12
2008	5
2009	4
2010	4
2011	3
2012	7
2013	9
2014	21
2015	22
2016	20
2017	8
2018	19
2019	15
2020	15
2021	13
2022	6
2023	2
2024	0

1

The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity.

Martin K, Müller P, Schreiner J, Prince SS, Lardinois D, Heinzelmann-Schwarz VA, Thommen DS, Zippelius A. Martin K, et al. Cancer Immunol Immunother. 2014 Sep;63(9):925-38. doi: 10.1007/s00262-014-1565-4. Epub 2014 Jun 7. Cancer Immunol Immunother. 2014. PMID: 24906866

2

Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells.

Müller P, Martin K, Theurich S, Schreiner J, Savic S, Terszowski G, Lardinois D, Heinzelmann-Schwarz VA, Schlaak M, Kvasnicka HM, Spagnoli G, Dirnhofer S, Speiser DE, von Bergwelt-Baildon M, Zippelius A. Müller P, et al. Cancer Immunol Res. 2014 Aug;2(8):741-55. doi: 10.1158/2326-6066.CIR-13-0198. Epub 2014 Apr 21. Cancer Immunol Res. 2014. PMID: 24916470

3

Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.

Kawano M, Itonaga I, Iwasaki T, Tsumura H. Kawano M, et al. Oncol Rep. 2013 Mar;29(3):1001-6. doi: 10.3892/or.2013.2224. Epub 2013 Jan 4. Oncol Rep. 2013. PMID: 23291864

4

Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.

da Cunha A, Antoniazi Michelin M, Cândido Murta EF. da Cunha A, et al. Immunol Lett. 2016 Sep;177:25-37. doi: 10.1016/j.imlet.2016.07.009. Epub 2016 Jul 14. Immunol Lett. 2016. PMID: 27423825

5

Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages.

Yang YF, Zou JP, Mu J, Wijesuriya R, Ono S, Walunas T, Bluestone J, Fujiwara H, Hamaoka T. Yang YF, et al. Cancer Res. 1997 Sep 15;57(18):4036-41. Cancer Res. 1997. PMID: 9307290

6

Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.

Kuhn S, Hyde EJ, Yang J, Rich FJ, Harper JL, Kirman JR, Ronchese F. Kuhn S, et al. J Immunol. 2013 Aug 15;191(4):1984-92. doi: 10.4049/jimmunol.1301135. Epub 2013 Jul 15. J Immunol. 2013. PMID: 23858033

7

CTLA-4 blockade enhances antitumor immunity of intratumoral injection of immature dendritic cells into irradiated tumor in a mouse colon cancer model.

Son CH, Bae JH, Shin DY, Lee HR, Choi YJ, Jo WS, Ho Jung M, Kang CD, Yang K, Park YS. Son CH, et al. J Immunother. 2014 Jan;37(1):1-7. doi: 10.1097/CJI.0000000000000007. J Immunother. 2014. PMID: 24316550

8

Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.

Okamoto M, Furuichi S, Nishioka Y, Oshikawa T, Tano T, Ahmed SU, Takeda K, Akira S, Ryoma Y, Moriya Y, Saito M, Sone S, Sato M. Okamoto M, et al. Cancer Res. 2004 Aug 1;64(15):5461-70. doi: 10.1158/0008-5472.CAN-03-4005. Cancer Res. 2004. PMID: 15289356

9

Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade.

Pai CS, Huang JT, Lu X, Simons DM, Park C, Chang A, Tamaki W, Liu E, Roybal KT, Seagal J, Chen M, Hagihara K, Wei XX, DuPage M, Kwek SS, Oh DY, Daud A, Tsai KK, Wu C, Zhang L, Fasso M, Sachidanandam R, Jayaprakash A, Lin I, Casbon AJ, Kinsbury GA, Fong L. Pai CS, et al. Immunity. 2019 Feb 19;50(2):477-492.e8. doi: 10.1016/j.immuni.2019.01.006. Epub 2019 Feb 5. Immunity. 2019. PMID: 30737146 Free PMC article.

10

Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.

Galea-Lauri J, Wells JW, Darling D, Harrison P, Farzaneh F. Galea-Lauri J, et al. Cancer Immunol Immunother. 2004 Nov;53(11):963-77. doi: 10.1007/s00262-004-0542-8. Epub 2004 May 14. Cancer Immunol Immunother. 2004. PMID: 15146294

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

190 results

Results by year